Dong-A Socio Holdings said it posted solid results last year on broad-based growth across major subsidiaries.
The company said Monday that its consolidated operating profit rose 19.1% from a year earlier to 97.8 billion won. Revenue increased 7.2% to 1.4298 trillion won.
In the fourth quarter, revenue rose 14.7% to 371.9 billion won, while operating profit fell 26.4% to 16.0 billion won from the same period in 2024.
Healthcare subsidiary Dong-A Pharmaceutical reported revenue of 726.3 billion won, up 7%, as all business segments grew. Operating profit rose 2% to 86.9 billion won.
Over-the-counter drug sales climbed 26.4% to 223.9 billion won, and the Bacchus fatigue drink business rose 2.1% to 270.0 billion won. The consumer health business fell 5.7% to 196.1 billion won.
Biopharmaceutical contract manufacturer STGen Bio posted revenue of 103.7 billion won, up 76.2%, driven by overseas commercialization of a Stelara biosimilar and expanded new orders. Operating profit jumped 323.4% to 7.1 billion won.
Logistics unit Yongma Logistics reported revenue of 423.8 billion won, up 5.8%, and operating profit of 21.0 billion won, up 10.6%.
Affiliate Dong-A ST, in which Dong-A Socio Holdings is the largest shareholder, said on a separate basis that operating profit fell 16.1% to 27.2 billion won last year, while revenue rose 16.3% to 745.1 billion won.
Fourth-quarter revenue increased 22.6% to a quarterly record 200.4 billion won, but operating profit swung to a loss.
Prescription drug revenue rose 19% to 527.8 billion won on higher sales of key products including growth hormone Grottropin and indigestion treatment Motilitone. Overseas business revenue increased 12.8% to 170.4 billion won, supported by biosimilar growth.
In R&D, Dong-A ST said it completed a Phase 2a trial of DA-1241, a treatment candidate for metabolic dysfunction-associated steatohepatitis and Type 2 diabetes being developed through its U.S. affiliate Metavia. It said a Phase 1a trial of obesity candidate DA-1726 is ongoing. The company also said it will run a Phase 1 trial in the first half for antibody-drug conjugate candidates targeting gastric and pancreatic cancers after acquiring ADC specialist AbTis. It said Phase 1 trials in South Korea are also underway for a dementia treatment and an immuno-oncology drug.
Another affiliate, CDMO company ST Pharm, reported operating profit of 55.1 billion won last year, up 98.9%, and revenue of 331.6 billion won, up 21.1%.
In the fourth quarter, ST Pharm posted revenue of 129.0 billion won and operating profit of 26.4 billion won, up 11.4% and 15.9%, respectively, from the same period a year earlier.
ST Pharm said results improved on growth in its oligonucleotide drug CDMO business. Annual oligonucleotide revenue rose 35% to 237.6 billion won, and its order backlog stood at 204.0 billion won at the end of last year. In January, it won a new single supply contract worth 83.0 billion won.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.